[Federal Register Volume 59, Number 242 (Monday, December 19, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-31069]


[[Page Unknown]]

[Federal Register: December 19, 1994]


=======================================================================
-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION

10 CFR Part 35

[Docket No. PRM-35-12]

 

Tri-Med Specialties, Inc.; Filing of Petition for Rulemaking, 
Correction

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice of receipt of petition for rulemaking; correction.

-----------------------------------------------------------------------

SUMMARY: This document clarifies a portion of the notice of receipt for 
a petition for rulemaking filed by Tri-Med Specialties, Inc., and 
docketed as PRM-35-12. The notice of receipt for this petition was 
published on December 2, 1994 (59 FR 61831).

DATES: Submit comments by February 15, 1995. Comments received after 
this date will be considered if it is practical to do so, but assurance 
of consideration cannot be given except as to comments received on or 
before this date.

ADDRESSES: Submit comments to the Secretary, U.S. Nuclear Regulatory 
Commission, Attention: Docketing and Service Branch, Washington, DC 
20555. For a copy of the petition, write to the Rules Review Section 
Rule Review and Directives Branch, Division of Freedom of Information 
and Publications Services, Office of Administration, U.S. Nuclear 
Regulatory Commission. Washington, DC 20555.

FOR FURTHER INFORMATION CONTACT: Michael T. Lesar, Chief, Rules Review 
Section, Rules Review and Directives Branch, Division of Freedom of 
Information and Publications Services, Office of Administration, U.S. 
Nuclear Regulatory Commission, Washington, DC 20555. Telephone: 301-
415-7163 or toll free: 1-800-368-5642.

SUPPLEMENTARY INFORMATION: In the notice of receipt for PRM-35-12 
published on December 2, 1994 (59 FR 61831), the paragraph under the 
heading, ``Benefits of the Test,'' revised to read as follows:
    The petitioner states that under the current regulations, the test 
is 95 percent accurate and quite inexpensive because of its simplicity. 
The test would permit doctors to determine easily whether or not ulcer 
patients have been cured of their infection. By providing the public 
with an inexpensive, easily accessible diagnostic test, more 
individuals would be accurately diagnosed and treated for H.pylori 
infection. This would save the United States an estimated $500 million 
per annum over conventional therapy.


    Dated at Rockville, Maryland, this 13th day of December, 1994.

    For the Nuclear Regulatory Commission.
Michael T. Lesar,
Chief, Rules Review Section, Rules Review and Directives Branch, 
Division of Freedom of Information and Publications Services, Office of 
Administration.
[FR Doc. 94-31069 Filed 12-16-94; 8:45 am]
BILLING CODE 7590-01-P